Evidence map›Paper›PMID 35530155›Full record

ReviewActa pharmaceutica Sinica. B2022

Gather wisdom to overcome barriers: Well-designed nano-drug delivery systems for treating gliomas.

Jiwei Cui, Yuanxin Xu, Haiyan Tu, Huacong Zhao, Honglan Wang, Liuqing Di, Ruoning Wang

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jiwei CuiCollege of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Yuanxin XuCollege of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Haiyan TuCollege of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Huacong ZhaoCollege of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Honglan WangCollege of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Liuqing DiCollege of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Ruoning WangCollege of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Nanjing University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Due to the special physiological and pathological characteristics of gliomas, most therapeutic drugs are prevented from entering the brain. To improve the poor prognosis of existing therapies, researchers have been continuously developing non-invasive methods to overcome barriers to gliomas therapy. Although these strategies can be used clinically to overcome the blood‒brain barrier (BBB), the accurate delivery of drugs to the glioma lesions cannot be ensured. Nano-drug delivery systems (NDDS) have been widely used for precise drug delivery. In recent years, researchers have gathered their wisdom to overcome barriers, so many well-designed NDDS have performed prominently in preclinical studies. These meticulous designs mainly include cascade passing through BBB and targeting to glioma lesions, drug release in response to the glioma microenvironment, biomimetic delivery systems based on endogenous cells/extracellular vesicles/protein, and carriers created according to the active ingredients of traditional Chinese medicines. We reviewed these well-designed NDDS in detail. Furthermore, we discussed the current ongoing and completed clinical trials of NDDS for gliomas therapy, and analyzed the challenges and trends faced by clinical translation of these well-designed NDDS.

Indexed as

Active ingredientsBiomimetic designsBlood‒brain barrierCascade targetingGliomaNano-drug delivery systemsNon-invasive strategiesResponsive delivery and releaseTraditional Chinese medicine

Identifiers

PMID35530155
PMCPMC9069319
OpenAlexW3195791842

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.